Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Consensus Rating of “Hold” by Brokerages

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has earned a consensus recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $7.60.

A number of research analysts have recently issued reports on the company. Needham & Company LLC dropped their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Friday, February 28th. Finally, Morgan Stanley lowered their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at approximately $26,000. Private Trust Co. NA purchased a new position in Recursion Pharmaceuticals in the 4th quarter valued at approximately $27,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 21.1% during the fourth quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company’s stock worth $52,000 after purchasing an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in Recursion Pharmaceuticals by 43.7% in the fourth quarter. NewEdge Advisors LLC now owns 7,847 shares of the company’s stock valued at $53,000 after purchasing an additional 2,387 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $4.33 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 1-year low of $3.79 and a 1-year high of $12.36. The stock has a market cap of $1.74 billion, a PE ratio of -2.83 and a beta of 0.99. The firm has a fifty day moving average price of $5.53 and a 200 day moving average price of $6.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The business had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. Recursion Pharmaceuticals’s quarterly revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the company posted ($0.39) EPS. As a group, sell-side analysts anticipate that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.